NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-RM-20-004 from the NIH Guide for Grants and Contracts
Notice NOT-RM-20-006 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-032 from the NIH Guide for Grants and Contracts
Notice NOT-EB-19-023 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HD-21-012 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to announce the re-competition of the National Centers for Translational Research in Reproduction and Infertility (NCTRI). The NCTRI will be administered through the Specialized Research Center (P50) award mechanism. These centers will form a national network that facilitates and accelerates bidirectional knowledge transfer between the laboratory and clinic with the ultimate goal of improving human reproductive health through research excellence and innovation.
Notice NOT-AG-20-008 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-20-020 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.
Funding Opportunity RFA-CA-20-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Funding Opportunity RFA-CA-20-018 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Funding Opportunity RFA-CA-20-019 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Funding Opportunity RFA-DK-19-036 from the NIH Guide for Grants and Contracts. This FOA will support the conduct of clinical trials designed to test the clinical safety and efficacy of artificial pancreas (AP) device systems with the objective of improving glycemic control, reducing acute complications and improving quality of life in people with difficult to control T1D when using standard of care therapies.
Funding Opportunity PA-20-068 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to produce health services research that will rigorously test promising interventions aimed at improving communication and coordination during care transitions.
Notice NOT-DE-20-003 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-037 from the NIH Guide for Grants and Contracts
Notice NOT-EY-20-002 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-036 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-033 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-034 from the NIH Guide for Grants and Contracts
Notice NOT-NS-20-028 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-21-001 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support a network to enhance collaborations across NIA's 6 centers programs. These collaborations are intended to leverage NIA's substantial investments by fostering and sustaining the development of novel interdisciplinary efforts in aging research. This opportunity will provide resources to build additional infrastructure and establish specific collaborative activities that could include, but are not limited to, information and data exchange, meetings and conferences, pilot studies, research opportunities for early investigators, visiting scholar programs, dissemination, and other collaborative efforts. The successful awardee will involve all 6 centers programs.